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, ,Hepatitis B virus (HEV) has been identified in a number of  nonhuman primate species, including 
" 'the Silvery gibbon CRylobates moloch).  The Perth Zoo has a successful Silvery gibbon breeding 
program  and has  developed an HBV vaccination regime  to  protect offspring of this  species, 
Serologic testing has demonstrated that this vaccination regime has been successful in producing 
a serologic response consistent withvaccine-induced immunity, 
Introduction 
Hepatitis B virus (HEV) infections involving strains that are distinct from human HEV genotypes, 
have been identified in gibbons (GiHEV), orangutans (OuHV), chimpanzees (ChHEV), gorillas 
(GoHEV) and woolly monkeys (WMHBV),  4,6,7, 13,14 Recent studies have demonstrated wide-spread 
infection of wild primate populations with these species-specific HBV infections.3 ,5,8,I,.14 Recent 
studies provide evidence that these viruses are  indigenous to  these nonhuman primate species, 
suggesting that a transmission event in the Old World between humans and nonhuman primates may 
have occurred, involving a common ancestor virus from which the nonhuman primate HEV  variants 
and the Old World human HEV genotypes (A to E) have evolved:,5,8,13 However, other researchers 
favour the theory that these nonhuman primate HEV variants are more likely the result of  recent 
cross-species transmission of the  virus between humans  and nonhuman primates.
6,7  Fulminant 
hepatitis has been reported in a woolly monkey infected with WMHBV,6 and elevated alanine 
. aminotransferase (ALT) levels were reported in gibbons infected with GiHBV.lO  However, the 
pathogenicity of the HEV infections in other nonhuman primate species remains unknown.7 ,14 
Experimental transmission of  hum  an HE  V to chimpanzees and gibbons has been documented,  1,10,11 
and infectivity of  gibbon HBV to a chimpanzee has also been demonstrated.9To date there is limited 
knowledge as to the zoonotic potential of  these nonhuman primate viruses. Although it seems likely 
that these viruses are potentially zoonotic,9 studies have not been able to confirm transmission of 
HEV from nonhuman primates to humans.'o 
The Perth Zoo currently houses one of the few  successful breeding colonies of Silvery gibbons 
(Rylobates moloch) in the world and the only one in the Australasian region. Serologic testing of 
the two breeding adults at the Perth Zoo has shown cross-reactions with human HEV antigens and 
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[HBsAg+veJ and negative for HBV surface antibody [anti-HBs -vell (Tables I and 2). The breeding 
female is further classified as a high-infectivity chronic carrier, due to the cross-reaction of  her sera 
with HBV e antigen (HBeAg). The likelihood that human babies born to high-infectivity chronic 
carrier mothers will develop HBv infection and become chronic carriers is greater than 90%, as 
compared to the 10-15% risk of infection associated with babies born to low-infectivity chronic 
carrier mothers.2,3 Although transmission studies of the disease in nonhuman primates have been 
limited, previous studies have demonstrated a similar perinatal transmission pattern to that ofHBV 
in humans:'? DNA sequencing currently being undertaken by the author has demonstrated that the 
HBV  -like  virus  isolated  from  the  breeding  female  at  the Perth Zoo  is  closely related  to  the 
previously identified GiHBV rather than human HBVY·1o 
An  unrelated adult male the Perth Zoo Silvery gibbon, who was also classified as a high- infectivity 
chronic carrier, died recently after a period of liver-related illness. This individual was found on 
postmortem to  have evidence of liver cirrhosis consistent with pathology seen in humans with 
chronic hepatitis B infection, and had demonstrated elevated levels of  ALTon multiple occasions 
(up to 613 U/L). 
Based on this info=ation, the Perth Zoo was concerned that there would be a high probability of 
offspring born to this Silvery gibbon breeding pair becoming infected with the virus, developing 
chronic carrier status, and possibly developing liver pathology associated with the infection in later 
life. Given the critically endangered status of  the species however, and the obvious compatibility 
of  the pair, it was decided to continue breeding these animals. A vaccination program to immunize 
newborn Silvery gibbons against HBV was developed with the help of  human virologists, to reduce 
the risk of  transmission of  the disease to future offspring. 
Development of an HBV Vaccination Regime 
The Silvery gibbon pair has given birth to four offspring since 1995, the most recent birth was in 
March 2003.  All four  offspring have been vaccinated against HBV.  The initial recommended 
vaccination regime involved vaccinating newborn gibbons within the first 24-72 hr of birth, with 
0.5 ml of  recombinant Hepatitis B vaccine (Energix B®, SmithKline Beecham Biologicals, B-1330 
Rixensart, Belgium) administered intramuscularly (i.m.) and 0.3  ml HBV Immunoglobulin (lao 
mimI) administered i.m. at a separate site. Booster vaccinations of  0.5 ml Energix B® vaccine i.m. 
were to be given at 4 mo and 12 mo  of age. The immunoglobulin administered with the  initial 
vaccination served to provide passive transfer of  immunity against potential viral exposure during 
the birthing process. Recommended doses to  be  used were extrapolated from human doses  and 
reduced according to body weight differences between the species. 
The vaccination regime was used on the first offspring (OF I), however the second booster Vias 
delayed to  15  mo  for  management reasons.  Blood testing  at  the  time  of the  second  booster 
demonstrated that this animal had developed a serologic response consistent with immunity to HBV. 
However, the presence of HBV core antibody (anti-HBc) as well as anti-HBs indicated that this 
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'sUI-fac:e antigen only, the presence of  core antibodies suggests that the animal has been exposed to 
'actual virus rather than just vaccine. It  is not possible from these results to detennine if  the anti-RBs 
resulted from exposure to vaccine, virus or a combination of  both. Repeat blood testing 5 yr after 
the initial vaccination showed that immunity had been maintained. Transfer of  this animal to another 
institution shortly after this time meant that further testing could not be performed. 
Due to the lack of serologic response to vaccination attained by the initial vaccination regime in 
OFl, the regime was amended for the second offspring (OF2) to involve a vaccination at 24-72 hr 
with 0.5 ml Energix B® vaccine i.m. and 0.1 ml HBV Immunoglobulin (100 ill/ml) i.m., followed 
by boosters of 0.5 ml Energix B® vaccine i.m. at I mo and 6 mo. Due to management and animal 
factors, the initial Energix B® vaccine and RBV Immunoglobulin injections were given at 72 hr, 
the first booster at 6 wk, and the second booster at 5 mo. Blood testing I yr after the second booster 
demonstrated that this animal had nb evidence of exposure to  the disease and had developed a 
serologic response consistent with vaccine-induced immunity (anti-HBc -ve, anti-HBs +ve). Serum 
from this individual was collected recently and has shown that this immunity has been maintained 
(4.5 yr after the initial vaccination)_ 
The third offspring (OF3) was vaccinated with 0.5 ml Energix B® vaccine i.m. and 0.1  ml RBV 
Immunoglobulin (100 ill/mI) i.m. at 48 hr, with a single booster of  0_5 ml Energix B® vaccine i.m. 
given at 8 mo.  This vaccination regime had been modified following discussions with human 
virologists, and the initial Energix B® vaccine booster (given previously at I mo) was eliminated 
due to problems encountered while darting the dam in order to vaccinate the previous offspring 
(OF2) at 1 mo of  age. Blood collected from OF3 2 yr after initial vaccination demonstrated that this 
animal had also developed a serologic response consistent with  vaccine-induced immunity and had 
no evidence of  exposure to the disease (anti-HBc -ve, anti-HBs +ve)_ 
Due to the success of  the modified vaccination regime used for OF3, this regime was repeated for 
the fourth offspring (OF4), born in March 2003. This baby was vaccinated with 0.5 ml Energix B® 
vaccine i.m. and 0.1 ml HBVImmunoglobulin (100 ill/ml) i.m. at 48 hr. A single booster of  0.5 ml 
Energix B® vaccine i.m. will be given at 8 mo. 
Discussion 
Based on serologic testing, the vaccination regimes used for OF2 and OF3  appear to  have been 
successful in producing vaccine-induced immunity that has been maintained for at least 2 yr since 
the initial vaccination. The regime used for OF3 was preferred since the booster vaccination at 8 mo 
was  able to be performed without the need for anesthesia of the dam.  All previous vaccinations 
given prior to this age required general anesthesia of the dam to allow access to the baby and to 
ensure good acceptance of the baby when returned to the dam. 
Although the initial regime used for OFI did not produce a serologic response consistent with 
vaccine-induced immunity, serology from  this  animal is  suggestive of immunity secondary to 
1\10 exposure to infection, and therefore OF 1 can now be safely involved in a breeding program without 
the risk of transmitting the disease to future offspring or other in-contact animals. 
Although the number of  animals in this study is low, it appears that the modified regime, involving 
vaccination at 24-72 hr with 0.5 ml Energix B® vaccine i.ill.  and 0.1  ml HEV Immunoglobulin 
(lOOIU/ml) i.m., followed by a booster vaccination of  0.5 ml Energix B® vaccine i.ill. at 8 mo, is 
successful  in  providing a  serologic response consistent with vaccine-induced immunity.  It is 
recommended that this vaccination regime be used for any future offspring born to this pair of 
Silvery gibbons at the Perth Zoo. Virologists have also recommended that repeat boosters ofEnergix . 
B® vaccine are given every 5 yr, on an opportunistic basis, in order to maintain immunity. 
Despite the apparent success of  the program, there are inherent risks to the dam, offspring and staff 
associated with the vaccination procedures, especially when darting and general anesthesia are 
involved. However, the benefits of  the vaccination procedure in successfully establishing vaccine 
induced-immunity in Silvery gibbon offspring at the Perth Zoo was deemed to outweigh the risks 
involved in the zoo's situation. The suitability of such a vaccination regime for other institutions 
would depend on the number and status of  the animals involved. 
The effectiveness of  vaccinations used in exotic species has often been questioned, as it is difficult 
to ascertain the extent of true protection afforded by vaccines that have been designed for other 
species (in this case, humans). This is  certainly applicable in this situation, and whether these 
animals are truly "immune" to infection is likely to be debatable. In a critically endangered species 
such as  the  Silvery gibbon, we do  not have the lUxury  of being able to  run challenge tests  to 
determine whether or not the immunity is truly protective. It  would appear though, that in the cases 
at the Perth Zoo true protection has been achieved as both OF2 and OF3 developed immunity that 
has been maintained for several years while living in very close contact with two chronic HBY 
carriers. The fact that OF 1 showed evidence of  exposure~induced immunity demonstrates that 
virus is transmissible in a captive situation, and as such there is a real risk of  infection to all 
offspring. Neither OF2 nor OF3 have shown evidence of exposure however, suggesting that thp;ro/;,',"'; 
vaccinations provided true protective immunity. An alternative explanation could be that the 
had seroconverted to become a low-infectivity carrier during the time between the birth of  OF 1 
OF2. In this scenario, the risk of  transmission of  the virus to the later offspring would be red.ucc:jl 
from> 90% to  10-15%. If this were the case, the serologic immunity demonstrated may not 
indicative oftrue protective immunity. However, serum samples collected from the dam at the 
of  vaccinating OF4 have confirmed she is still a high-infectivity carrier, supporting the 
the immunity attained in OF2 and OF3 is truly protective. 
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